elexacaftor tezacaftor ivacaftor
Selected indexed studies
- Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. (N Engl J Med, 2019) [PMID:31697873]
- Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events. (Am J Respir Crit Care Med, 2024) [PMID:37890129]
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. (Lancet Respir Med, 2025) [PMID:39756424]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. (2019) pubmed
- Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events. (2024) pubmed
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. (2025) pubmed
- Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review. (2023) pubmed
- Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. (2022) pubmed
- Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation. (2025) pubmed
- Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor. (2025) pubmed
- Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy. (2024) pubmed
- PMID:39965067 (2024) pubmed
- The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study. (2024) pubmed